No Photo Available

Last Update


This profile was last updated on .

Is this you? Claim your profile.

Wrong Shelley Boyd?

Dr. Shelley R. Boyd

President and CSO

Translatum Medicus

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Translatum Medicus

Background Information

Employment History

Clinician - Scientist

St. Michael's Hospital

Head of the Ocular Angiogenesis Research Program Worldwide

Novartis AG

Network Researcher

McMaster University


Clinical Research Fellow
University College London

President & CSO




Web References (55 Total References)

Shelley ... [cached]

Shelley Boyd President and Chief Scientific Officer

Dr Shelley Boyd is an Ophthalmologist and Clinician-Scientist at St Michael's Hospital, specializing in diseases of the retina - specifically Age-related Macular Degeneration (AMD). She also holds appointments as an Assistant Professor in the Department of Ophthalmology and Vision Sciences (DOVS) and the Department of Laboratory Medicine and Pathobiology (LMP) at the University of Toronto, as well as Adjunct Assistant Professor in Biomedical Engineering at McMaster University.
Dr Boyd was previously Head of the Ocular Angiogenesis program, worldwide, with Novartis Pharmaceuticals overseeing their successful translational research program in "wet" AMD that brought today's treatment from bench to bedside. Learning from this experience, she now uniquely aligns her knowledge of science, medicine and the pharmaceutical industry to finding new treatments for "dry" AMD.
In 2014, Dr Boyd established Canada's only dedicated High-Risk Dry AMD clinic and offers specialized imaging and research programs for patients with high-risk disease. She also heads a research laboratory which develops new theories and techniques, and investigates therapeutic options for dry AMD with the goal of translating the pre-clinical work to the clinic.

Shelley Boyd, MD, president ... [cached]

Shelley Boyd, MD, president and CSO, Translatum Medicus Inc. (TMi), reports the company has started raising capital to initiate preclinical studies - and possibly Phase II clinical trials - of TMI-018, a drug candidate that might convert potentially destructive macrophages. The company is building a case that aggressive M1 macrophages are the cause of retinal damage and geographic atrophy brought on by Dry AMD. Dr. Boyd says animal studies of TM1-018 suggest those destructive macrophages can be reverted to "neutral" M2 macrophages that perform more of a housekeeping role within the eye. She says TMI has developed an animal model to test TMI-018 as a means of reducing the retinal damage. Dr. Boyd in addition announced the company has expanded its management team and scientific advisory board. It's also been selected as a charter member of the JLabs incubator in Toronto. TMI hopes to begin preclinical trials next year.

Presenter: Shelley-Boyd
Shelley Boyd, MD, FRCSC
Shelley Boyd, MD, FRCSC, is an Ophthalmologist specializing in diseases of the retina and founding President & CSO of Translatum Medicus Inc(TMi).

1:21 - 1:27 | Translatum Medicus ... [cached]

1:21 - 1:27 | Translatum Medicus inc (TMi) | Shelley Boyd, MD, President & CSO

Translatum Medicus Inc. was ... [cached]

Translatum Medicus Inc. was founded by Dr Shelley Boyd, an Ophthalmologist specializing in diseases of the retina, and scientist at St Michael's Hospital.

In addition to her focus on science and medicine, Dr Boyd was formerly Head of the Ocular Angiogenesis Research Program worldwide for Novartis Pharmaceuticals, Switzerland, and helped bring today's treatment for wet AMD to patients around the globe. She uniquely aligns her knowledge of science, medicine and the pharmaceutical industry, and combines this with her passion for patient care.
Dr. Boyd is Founding Director of the only Canadian "High Risk Dry AMD Clinic" at St Michael's Hospital, Toronto, and the Ophthalmology Patient Education & Research Centre (Eye-PERC). 4 studies are currently under way.

Shelley Boyd, MD, President ... [cached]

Shelley Boyd, MD, President & CSO - Translatum Medicus

Similar Profiles

Other People with this Name

Other people with the name Boyd

Alex Boyd
The Tom James Company

LeAnn Boyd
Southern Scripts LLC

Vernon Boyd
Keller Williams Realty Inc.

Garrett Boyd
International Center for Leadership in Education

Yvette Boyd
Continuum Health Alliance LLC

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory